Table 9.

Efficacy of 150 mg simeprevir QD plus PegIFNα/RBV for 12w + PegIFNα/RBV for 12w.

Cirrhosis	Prior treatment	SVR12 rate in GT-1	Study and trial phase	Ref.
No cirrhosis	Naïve	80.5% (62/77)	PILLAR, phase 2b	Fried et al., 2013
	Naïve	88.6% (109/123)	CONCERTO-1, phase 3	Hayashi et al., 2014
	Non-response	52.8% (28/53)	CONCERTO-2, phase 3	Izumi et al., 2014
	Relapse	95.9% (47/49)	CONCERTO-3, phase 3
	Naïve	91.7% (22/24)	CONCERTO-4, phase 3	Kumada et al., 2015a
	Non-response	38.5% (10/26)
	Relapse	100% (29/29)
	Relapse	78.2% (230/294)	PROMISE, phase 3	Forns et al., 2014
	Naïve	82.1% (188/229)	QUEST-1, phase 3	Jacobson et al., 2014
	Naïve	81.8% (189/231)	QUEST-2, phase 3	Manns et al., 2014
	Null response	50.3% (87/173)	ATTAIN, phase 3	Reddy et al., 2015a
	Partial response	72.9% (86/118)
Cirrhosis	Relapse	74.4% (29/39)	PROMISE, phase 3	Forns et al., 2014
	Null response	24.6% (15/61)	ATTAIN, phase 3	Reddy et al., 2015a
	Partial response	55.6% (15/27)
	Naïve	58.1% (18/31)	QUEST-1, phase 3	Jacobson et al., 2014
	Naïve	64.7% (11/17)	QUEST-2, phase 3	Manns et al., 2014